2012 ASH Abstracts

FISH and GEP Based Prediction of Chromosomal Translocation Identifies Myeloma Patients Who Do Not Benefit From Bortezomib

Combining Proteomics and Gene Expression Profiling Identifies Proteins/Genes Associated with Short Overall Survival in Multiple Myeloma

18-FDG PET Focal Lesion and Avidity Suppression As Early As Day-7 Post-Induction Chemotherapy Predicts for Superior Outcome in Newly Diagnosed Multiple Myeloma Patients Treated with Total Therapy 3 Trials

DNA Flow Cytometry and Metaphase Cytogenetics Can Predict Progression of Asymptomatic Monoclonal Gammopathies (AMG) to Symptomatic Multiple Myeloma (MM)

Prognostic Significance of DNA/Cig Flow Cytometry Assay in the ‘’era’’ of Novel Therapies in Multiple Myeloma (MM)

Hyperhaploid Multiple Myeloma (MM): A Rare Karyotypic Subgroup Retaining Disomy 18 and 1q12~23 Amplification

The Antimalarial Agent Artesunate Overcomes Bortezomib Resistance in Myeloma Cell Lines Through Non-Caspase Mediated Apoptosis

Metaphase Cytogenetic Abnormality (CA) Subtypes in Multiple Myeloma (MM) Treated with Front Line Total Therapy (TT) Protocols TT1, TT2, TT3, TT4 and TT5

Identifying the Outliers Among Gene Expression Profiling (GEP)-Defined Low-Risk Myeloma Patients Treated with Total Therapy 2 and 3 (TT2, TT3)

Gene Expression Profiling (GEP) of Whole Bone Marrow Biopsies in Complete Remission (BMB-CR) of Multiple Myeloma (MM) Patients Treated On Total Therapy  Protocols – Normalization of GEP Signature in Comparison with Normal Donor BMB (BMB-NL) and Consequences for Progression-Free Survival (PFS)

Secondary Myelodysplasia-Associated Metaphase Cytogenetic Abnormalities in Newly Diagnosed Multiple Myeloma Treated On Total Therapies 2 & 3– Influence of Cumulative Dosing of Maintenance Drugs

Fresh Ex Vivo Expanded Natural Killer Cells Demonstrate Robust Proliferation in Vivo in High-Risk Relapsed Multiple Myeloma (MM) Patients

 Fulminant Onset of Acute Leukemia (FOAL) After Total Therapies (TT) for Multiple Myeloma (MM): Absence of MDS Pathological Criteria within 3 Months of Prior MM Follow-up

 Curing Multiple Myeloma (MM) with High-Risk Features Defined by Metaphase Cytogenetic Abnormalities (CA), High LDH (>300U/L) and Gene Expression Profiling (GEP)-70 Score >=+o.66

 Expanded Natural Killer (NK) Cells for Immunotherapy: Fresh and Made to Order

Renal Function Impairment (creatinine>=2mg/dL) Limits Progress Noted with the Transition From Total Therapies TT1 to TT2 to TT3 Across Age Groups

Patterns of CNS Involvement in Relapsed and/or Refractory Multiple Myeloma

Gene Expression Profiling (GEP) in MGUS and AMM: Predictors of Progression

High CCN1 Levels Are Associated with Longer Progression-Free and Overall Survival in GEP-Defined High-Risk Myeloma

Gene Expression Profiling (GEP) of Whole Bone Marrow Biopsies (BMB) in Multiple Myeloma (MM) – Relationship to Plasma-Cell (PC)-Based GEP-Defined Risk and Molecular Subgroups

Abnormal Hevylite Assay Ratio As a Prognostic Marker for Survival in Newly Diagnosed Multiple Myeloma Patients Treated On Total Therapy 3

Carfilzomib Induces Differentiation of Mesenchymal Stromal Cells Toward Osteoblast  Via Activation of β-Catenin/TCF Signaling

Myeloma Can Modulate Expanded Natural Killer Cell Function Through Multiple Mechanisms

Phase II Study of Pomalidomide (Pom) in Genomically Defined High Risk Relapsed and Refractory Multiple Myeloma (RRMM)

Reduced HMOX1 Expression in Myelomatous Bones Is Associated with Poor Survival and Its Induction Regulates Osteoclastogenesis and Osteoblastogenesis

HMOX1 Is a Targeted Therapy for Myeloma-Induced Bone Disease

Hematopoietic Progenitor Cell (HPC) Collection Is Feasible in Previously Transplanted Multiple Myeloma Patients and Plerixafor Improves Collection